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ABSTRACT 
Objective: The primary objective of the present work was to formulate the gastro-retentive delivery system of ketoconazole (ktz) for its extensive 
absorption in the stomach.  
Methods: The solubility and dissolution of antifungal ktz were reported to be higher in the stomach than in the intestinal pH conditions because of its 
dibasic pKa values 6.51 and 2.94. Thus the development of target buoyant tablets using Hydroxy Propyl Cellulose (HPC) and Xanthan gum (Xg) as 
polymers along with the effect of citric acid and sodium bicarbonate as an effervescent causing agent of floatation properties and drug release profile 
was investigated. The formulation optimization was carried out by using a central composite design using Design Expert software by taking HPC, 
Xanthan gum and sodium bicarbonate as independent variables and floating lag time, in vitro drug release profile as dependent variables respectively. 
Results: The optimized formulation of ktz buoyant tablets could be developed. The amount of HPC and Xg was found to significantly influence all in 
vitro response parameters. The results of pre-compression and post-compression parameters of all the formulations were found to be within the 
standard limits. The optimized formulation exhibited floating lag time of 160 secs with sustained drug release over a period of 12 h in simulated 
stomach pH condition.  
Conclusion: Buoyant tablets of ktz with sustained drug release over a period of 12 h in simulated stomach conditions for enhanced drug absorption 
could be successfully developed. 
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ktz is a broad-spectrum anti-mycotic drug having two pKa values(6.51 
and 2.94) with poor water solubility and short elimination half-life of 2 
h [1]. It is a drug of choice for treatment of candidiasis, oral thrush, 
candiduria and paracoccidioidomycosis. It has been reported that the 
solubility and dissolution of ktz have found to be increased in the 
stomach pH than in the intestinal pH conditions. Thus in the present 
study, an attempt has been made to formulate ketoconazole into a 
floating drug delivery system to prolong its gastric residence time with 
an increase in its dissolution and absorption. As for reliable retention 
behavior in the stomach, the design of dosage form, food effects and 
the complex motility of the stomach poses a major challenge to the 
formulator [2]. The controlled gastric retention of solid dosage forms 
may be achieved by the mechanisms of mucoadhesion [3, 4] flotation, 
sedimentation [5, 6] expansion, modified shape systems [7, 8] or by 
the simultaneous administration of pharmacological agents [9, 10] 
that delay gastric emptying. 
The floating drug delivery system (FDDS) have a bulk density lower 
than gastric fluid and thus remain buoyant in the stomach without 
affecting the gastric emptying rate for a prolonged period of time. 
Based on the mechanism of buoyancy, two distinctly different 
technologies, i.e. with effervescent and without effervescent systems 
have been used in the development of FDDS. The effervescent 
system uses matrices prepared with swellable polymers and 
effervescent components e. g. sodium bicarbonate and citric acid or 
tartaric acid. In non-effervescent FDDS, the drug mixes with a gel-
forming hydrocolloid, which swells in contact with gastric fluid after 
oral administration to maintain a relatively stable shape and a bulk 
density of less than unity within the outer gelatinous barrier. The air 
trapped by the swollen polymer confers buoyancy to these dosage 
forms [11]. 
In the present investigation, an attempt to increase the dissolution was 
made by developing gastro-retentive floating tablets of ktz using HPC, 
Xg as a gel-forming agent and also release retardant agent with citric 
acid-sodium bicarbonate as effervescent components.  
MATERIALS AND METHODS 
ktz and Xg were purchased from Yarrow chem. Product, Mumbai. 
HPC was purchased from Himedia Laboratories Pvt. Ltd, Mumbai. All 
other ingredients, reagents and solvents were of analytical/ 
laboratory grade. 
Design of formulations 
Formulations were developed using a central composite design after 
results obtained through conducted pre-formulation trials. The 
Design-Expert Software (version 8.0.1, Stat-Ease Inc., Minneapolis, 
USA) suggested eight model formulations as shown in table 1 
considering the concentration of HPC, Xanthan gum and sodium 
bicarbonate as independent variables with the percentage drug 
release, floating lag time as dependent variables. 
 
Table 1: Central composite design response for three factors 
 Run Formulation code Type Factor 1: A  
HPC 
Factor 2: B xanthan gum Factor 2:  B sodium 
bicarbonate 
 1 OFT-1 Factorial 50 50 50 
 2 OFT-2 Factorial 50 150 50 
 3 OFT-3 Factorial 150 150 100 
 4 OFT-4 Factorial 150 150 50 
 5 OFT-5 Factorial 150 50 100 
 6 OFT-6 Factorial 150 50 50 
 7 OFT-7 Factorial 50 150 100 
 8 OFT-8 Factorial 50 50 100 
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Formulation development of ketoconazole buoyant tablets  
Floating tablets of ktz were prepared using the values given in table 
1 by wet granulation technique with a constant concentration of 
citric acid and varied concentration of sodium bicarbonate as 
effervescent agents as shown in table 2. Weighed quantities of drug 
and polymer were mixed homogeneously using mortar and pestle. 
PVP-K30 (5% w/v) solution in alcohol was used as a granulating 
agent. Granules were prepared by passing wet coherent mass 
through a BSS # 12 sieve. The obtained granules were dried at 40⁰C 
temperature for 30 min. The dried granules were sieved through 
BSS # 16, sodium bicarbonate and citric acid were mixed and 
blended with magnesium stearate and talc. Lubricated granules 
were compressed into tablets using ten stations single rotary 
punching machine (Rimek RSB-4 mini press) using 12 mm punches 
and die to obtain tablets of desired specifications. 
 
Table 2: Formulation table for trials given in optimization design 
Ingredients Quantity(mg) 
OFT-1 OFT-2 OFT-3 OFT-4 OFT-5 OFT-6 OFT-7 OFT-8 
Ketoconazole 200 200 200 200 200 200 200 200 
HPC 150 150 150 50 50 50 50 150 
Xanthan Gum 150 50 50 150 50 150 50 150 
Sodium bi carbonate 50 50 100 100 50 50 100 100 
Citric acid 25 25 25 25 25 25 25 25 
Lactose 60 160 110 110 260 160 210 10 
Mg stearate 10 10 10 10 10 10 5 5 
Purified talc 5 5 5 5 5 5 10 10 
Total weight(q. s) 650 650 650 650 650 650 650 650 
 
Evaluation studies  
Drug-polymer compatibility studies by FTIR and DSC  
The drug and polymer interactions were studied by FTIR 
spectroscopy using KBr disc method. The spectra were recorded for 
pure drug, polymers and physical mixture of drug and polymer in 
the ratio 1:1 at the scanning range of 400-4000 cm-1 using FTIR-
8400 S, spectrophotometer (SHIMADZU, Japan). DSC studies were 
also carried out to check the compatibility of the drug with polymers 
used in formulation design.  
Pre-compression studies 
The flow properties of granules (before compression) were 
characterized in terms of angle of repose, tapped density, bulk 
density, Carr’s index and Hausner ratio [12]. 
Post-compression studies 
Six tablets from each batch formulation were randomly selected and 
organoleptic properties such as color, odor and shape were evaluated. 
Thickness and diameter of ten tablets were measured using vernier 
calipers. Prepared floating tablets were evaluated for uniformity of 
weight using 20 tablets, hardness (Monsanto tester), friability using 10 
tablets (Roche Friabilator, Koshiash Industries, Mumbai). 
Determination of swelling index 
The swelling index of tablets was determined in 0.1N Hcl (pH 1.2) at 
room temperature. The swollen weight of the tablet was determined 
at predefined time intervals over a period of 5 h. The sample tablet 
from each batch was weighed and placed in a petri dish containing 
10 ml of 0.1N HCl. After each hour the tablet was removed from a 
petri dish, excess solvent on the surface of the tablet was blotted 
with the paper gently and weighed again up to 5 h. The percentage 
of weight gain by the tablet was calculated by using the formula [12]. 
Swelling index (S. I.) = {(Wt-Wo)/Wo} x 100 
Where S. I. = Swelling index, 
Wt = Weight of tablet at time t, 
Wo = Weight of tablet before immersion. 
Drug content 
Twenty tablets from each batch were randomly sampled, weighed 
and powdered. Tablet triturates equivalent to the average weight of 
the tablets was dissolved in 0.1 N HCl in 100 ml volumetric flask. The 
sample solution was further diluted and the absorbance was 
measured at 269 nm using 0.1N HCl as blank and the % drug content 






Drug content (mg) = concentration x dilution factor 
% Drug content= 
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In vitro buoyancy studies 
The tablets individually were placed in a 100 ml beakers containing 
0.1N HCl. The in vitro buoyancy was determined by the floating lag-
time (time period between placing the tablet in the medium and the 
tablet floating). The duration up to which the tablet floats on the 
dissolution medium was taken as duration of buoyancy. The studies 
were carried out in triplicate [14]. 
In vitro dissolution study 
In vitro dissolution studies were carried out in 900 ml of 0.1N HCl as 
the dissolution medium for 12 h using USP type II dissolution 
apparatus (Shimadzu TDT 08L dissolution tester). The rpm of the 
paddle was kept at 50 rpm and the temperature was maintained at 
37 °C±0.5 °C. A sample (2 ml) of the solution was at regular 
predetermined time intervals and the volume replaced with fresh 
dissolution medium. The withdrawn samples were diluted suitably 
and the absorbance was measured at 269 nm by using UV/Visible 
Spectrophotometer [15, 16]. 
Development of optimized RFT formulation  
In order to accurately optimize a probable formulation to attain 100% 
drug release in 12 h, the evaluation results obtained from eight 
formulation trials were further predicted using Design Expert 
software. One such response (formulation design) was experimentally 
tested to check whether the predicted values assumed by the software 
matches with the experimental results in terms of floating time and 
dissolution rate as indicated in table 6 and fig. 1. 
RESULTS AND DISCUSSION 
FTIR studies 
The combined IR spectrum of ktz showed the characteristic 
absorption peaks at 3236, 3062, 1581 and 1265 cm-1 denoting 
stretching vibrations of–NH, aromatic–CH,–NH bending and an 
aromatic C-O group respectively. In case of HPC a peak was observed 
at 2885.31 cm-1 indicating the presence of the primary alcoholic 
group present in the molecule. Another prominent peak appeared at 
1249.79 cm-1 suggesting it as an C-O-C stretch. The FTIR spectra of 
the pure Xg showed a broad absorption peak at 3637.50 cm−1 
indicating the hydrogen bond-OH groups,, 2887.24 cm-1indicatingC-
H aromatic stretch,1274.86 cm-1indicating an C-O-C stretch, 1730.03 
cm-1 indicating C=O stretch. The IR spectra of physical mixture drug-
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polymer blends showed neither shift nor disappearance of 
characteristic peaks when compared with IR-spectrum of pure 
sample suggesting that there was no interaction between drug and 
polymers as shown in fig. 2. 
  
 
Fig. 1: Parameters suggestions for RFT formulation 
 
 
Fig. 2: IR spectra of Ketaconazole, physical mixture of Ketaconazole-HPC and Ketaconazole-Xanthangum 
 
DSC studies 
The DSC thermograms of the drug and polymer tested are shown in 
fig 3. DSC curve of ktz exhibited endothermic peak (150.15 °C) 
corresponding to the melting point of the drug and immediately 
followed by sharp symmetric exothermic peak (154 °C) due to its 
degradation. The physical mixture of drug-polymer blends, 
ketoconazole with HPC and ketoconazole with xanthan gum 
exhibited sharp peak of the drug without any changes. Thus the drug 
was found to be stable with the polymer used in the formulation. 
 
 
Fig. 3: DSC thermogram of ktz, physical mixture of ktz-HPC and ktz-xanthan gum 
 
Pre-compression evaluation for optimization trials given in the 
design 
The values of bulk density were found to be in the range from 0.344 
to 0.506 g/cc; tapped density in the range of 0.389 to 0.590 g/cc, 
which indicated that the powder blends were having good flow 
properties. The Hausner’s and compressibility index, angle of repose 
values for the formulations showed good flow properties as 
indicated in table 3. 
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Table 3: Pre-compression results for optimization trials given in the design 




Angle of repose (Ɵ) Carr’s index 
(%) 
Hausner’s ratio 
OFT-1 0.481±0.001 0.56±0.001 27 ° 75′ 14.25 1.164 
OFT-2 0.387±0.001 0.442±0.0015 28 ° 59′ 12.61 1.143 
OFT-3 0.441±0.001 0.506±0.001 24 ° 24′ 12.47 1.143 
OFT-4 0.506±0.001 0.590±0.001 26 ° 41′ 14.20 1.165 
OFT-5 0.459±0.001 0.536±0.001 24 ° 24′ 14.17 1.167 
OFT-6 0.487±0.001 0.569±0.001 23 ° 06′ 14.37 1.166 
OFT-7 0.457±0.001 0.533±0.0015 25 ° 55′ 14.39 1.166 
OFT-8 0.344±0.001 0.389±0.001 29 ° 54′ 12.08 1.123 
*Mean valve±SD (n=3) 
 
Post-compression evaluation for optimization trials given in the 
design 
All the tablets were found to be capsulate with no cracks. All the 
batches prepared (OFT1-OFT8) showed hardness in the range of 
5.80 to6.80 kg/cm2with good mechanical strength for the tablets. 
Further friability values below 1% ensured the same. The 
formulation batches passed all the official tests for tablets. The 
floating lag time and total floatation time were recorded between 
125-310 secs and 21-24 h respectively as indicated in table 4. 
 
Table 4: Post-compression results for optimization trials given in design 












OFT-1 5.80±0.11 650±3 0.92 98.18±4.30 125 21 
OFT-2 6.20±0.3 649±9 0.87 99.16±3.25 150 24 
OFT-3 6.40±0.2 650±7 0.93 98.49±5.15 270 23 
OFT-4 6.80±0.2 650±5 0.89 99.10±4.25 310 21 
OFT-5 5.80±0.2 650±9 0.88 97.65±6.05 245 22 
OFT-6 6.40±0.4 650±7 0.89 98.76±5.21 270 24 
OFT-7 6.20±0.4 648±8 0.82 99.57±4.14 235 23 
OFT-8 6.80±0.3 649±6 0.83 98.64±6.10 145 24 
*Mean valve±SD (n=3) 
 
 
Fig. 4: Comparative bar chart for swelling index of formulations, mean±SD (n=3) 
 
 
Fig. 5: In vitro drug release profile of formulations OFT: 1-8 
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Swelling index  
The swelling index was studied for 5 h in 0.1N HCl and the results 
indicated in fig. 4. The swelling property was directly proportional 
to the concentration of the polymer, which may be attributed to the 
hydrophilic property of the polymer and also to its concentration in 
the dosage form. 
In vitro dissolution studies 
The comparative in vitro drug release profile for 12 h of all the 
formulations (fig. 5) OFT-1(98.4%),OFT-2(86.4%),OFT-3(84.8%), 
OFT-4(76.8%),OFT-5(94.1%),OFT-6 (88.4%), OFT-7(83.9%), OFT-8 
(101.1%) showed extended drug release at the end of 12h in the 
simulated stomach pH conditions. 
Drug release kinetic studies 
In order to establish the mechanism of drug release, the 
experimental data were fitted into various kinetic models. It was 
observed that the highest correlation was found for the first order 
and Korsmeyer equation which indicated the drug release occurred 
by diffusion mechanism. Release of drug from matrix tablet 
containing hydrophilic polymers generally involves factors of 
diffusion. Diffusion is related to transport of drug from the dosage 
matrix into the in vitro study fluid depending upon the concentration 
[17, 18]. The correlation values of the first-order equation of all 
formulations were found to be in the range 0.9327 to 0.9957. To 
confirm the diffusion mechanism, the data were fitted into 
Korsmeyer equation. All the formulations showed the ‘n’ value 
between 0.3 to 1; signifying non-fickian diffusion table 5 i.e.; the 
drug diffuses partly through the swollen matrix and gradually 
expanding hydrated matrix with increasing diffusion path length. 
Optimized formulation (RFT) 
Predicted vs. experimental values of optimized RFT formulation has 
been reported in table 6. The values of pre-compression and post-
compression parameters of the RFT formulation were found to be 
within the IP limits. The floating lag time and percentage drug 
release in 12 h. were found to be 160 sec. and 100 % respectively 
which was comparable with the predicted results obtained from the 
Design Expert software. The release rate followed the non-fickian 
diffusion mechanism as its “n” value was found to be 0.5423with 
best fit model as a matrix type. 
 
Table 5: Formulation drug release kinetics model 
Code Kinetic models 
Zero-order plot First-order plot Matrix plot Korsmeyer peppas Hix. crow plot  
r2 K r2 K r2 K r2 N K r2 K 
OFT-1 0.976 8.006 0.989 -0.148 0.970 -0.148 0.998 0.763 13.417 0.997 -0.0039 
OFT-2 0.933 6.957 0.986 -0.110 0.981 20.258 0.973 0.527 18.840 0.979 -0.0313 
OFT-3 0.953 7.051 0.992 -0.112 0.961 20.392 0.965 1.055 6.735 0.984 -0.0317 
OFT-4 0.958 6.197 0.995 -0.099 0.979 17.965 0.992 0.688 12.172 0.988 -0.0265 
OFT-5 0.756 7.365 0.932 -0.122 0.958 21.788 0.911 0.322 30.541 0.907 -0.0339 
OFT-6 0.981 6.989 0.995 -0.113 0.958 20.067 0.997 0.853 9.679 0.9923 -0.0317 
OFT-7 0.975 6.701 0.994 -0.104 0.948 19.218 0.994 1.044 6.353 0.9926 -0.0297 
OFT-8 0.986 8.117 0.981 -0.156 0.955 23.261 0.996 0.883 10.564 0.9955 -0.0407 
 
Table 6: Generalized optimization solution data predicted vs. actual 
Number HPC Xanthan gum Sodium bicarbonate Cumulative %drug release 12h Floating lag time (sec) 
1 50 55.55 100 99.99 145.696 
2 50 55.24 98.64 99.95 146.952 
3 50 54.49 100 99.99 148.021 
4 50 50 88.36 99.96 156.72 
5 50 50 74.34 99.066 169.344 
RFT  (Experimental) 50 55 100 100.55 160 
 
 
Fig. 6: In vitro drug release kinetics of RFT formulation 
 
CONCLUSION 
The development of optimized buoyant tablets of ktz with an 
increase in solubility and dissolution profile with extended drug 
release for a period of 12 h in simulated stomach pH conditions 
could be successfully achieved. The results opens a new insight 
about using the design of formulation softwares by providing 
polymer manipulations necessary to optimize formulation variables 
to obtain the desired outcome with respect to drug release, floating 
time or any other parameters.  
The net result of this research work was the formulation of a stable, 
floating Ktz formulation with 12 h in vitro drug release which may 
be tested for in vivo bioavailability studies in suitable animal models.  
Ghosh et al. 
Int J App Pharm, Vol 11, Special Issue 2, 2019, 18-23 
 
Innopharm3 | 3rd International Conference on Academic and Industrial Innovations: Transitions in Pharmaceutical, Medical and Biosciences                  | 23 
ACKNOWLEDGMENT 
The authors are thankful to M. S. Ramaiah University of Applied Sciences 
for providing necessary facilities to carry out the research work. 
AUTHORS CONTRIBUTIONS  
All the author have contributed equally 
CONFLICT OF INTERESTS  
Declared none 
REFERENCES 
1. Gilbert SB, Christopher TR. Modern Pharmaceutics. 4th ed. 
Marcel Dekker Inc publishing; 2005. p. 501-5.  
2. Kumar R, Patil S, Patil MB, Patil SR, Paschapur MS. Design and 
in vitro evaluation of oral floating matrix tablets of aceclofenac. 
Int J ChemTech Res 2009;1:815-25. 
3. Ponchel G, Irache JM. Specific and non-specific bioadhesive 
particulate system for oral delivery to the gastrointestinal tract. 
Adv Drug Delivery Rev 1998;34:191-219. 
4. Lenaerts VM, Gurny R. Gastrointestinal tract-physiological 
variables affecting the performance of oral sustained release 
dosage forms. In: Lenaerts V, Gurny R. eds. Bioadhesive Drug 
Delivery System. Boca Raton, FL: CRC Press; 1990. 
5. Rednick AB, Tucker SJ. Sustained release bolus for animal 
husbandry. US patent 3507952; 1970. 
6. Davis SS, Stockwell AF, Taylor MJ. The effect of density on the 
gastric emptying of single and multiple unit dosage forms. 
Pharm Res 1986;3:208-13. 
7. Fix JA, Cargill R, Engle K. Controlled gastric emptying. III. 
Gastric residence time of a non-disintegrating geometric shape 
in human volunteers. Pharm Res 1993;10:1087-9. 
8. Kedzierewicz F, Thouvenot P, Lemut J, Etienne A, Hoffman M, 
Maincent P. Evaluation of peroral silicone dosage forms in 
humans by gamma-scintigraphy. J Controlled Release 
1999;58:195-205. 
9. Groning R, Heun G. Oral dosage forms with controlled 
gastrointestinal transit. Drug Dev Ind Pharm 1984;10:527-39. 
10. Groning R, Heun G. Dosage forms with controlled 
gastrointestinal passage studies on the absorption of nitro-
furantion. Int J Pharm 1989;56:111-6. 
11. Villafuerte RL, Quirino BT, Jimenez MI. Sustained delivery of 
captopril from floating matrix tablets. Int J Pharm 
2008;362:37-43. 
12. Debajyoti R, Amresh KP. Designing and in vitro studies of 
gastric floating tablets of tramadol hydrochloride. Int J Appl 
Pharm 2010;2:12-6. 
13. Devendra KB, Peeyush B, Akash Y, Sarita K. Development and 
characterization of floating tablets of captopril using natural 
polymers. Pharma Res 2009;1:213-22. 
14. Rosa M, Zia H, Rhodes T. Dosing and testing in vitro of a 
bioadhesive and floating drug delivery system for oral 
application. Int J Pharm 1994;105:65-70. 
15. Shreeraj HS, Jayvadan KP, Nirav VP. Formulation and 
evaluation of effervescent floating tablet of Levofloxacin 
against H. pylori infection. Der Pharm Sin 2010;1:232-44.  
16. Bolai P, Senthil A, Mohd JQ, Nahlah EI. A review of helicobacter 
pylori infection diseases, antibiotic resistance and diagnosis. 
Asian J Pharm Clin Res 2018;11:566-71. 
17. Formulation and in vitro evaluation of salbutamol sulphate and 
theophylline extended-release tablets using modified 
polymers. Int J Pharm Pharm Sci 2018;10:67-71,  
18. Ain S, Kumar B, Pathak K. Development and characterization of 
controlled release famotidine matrix tablets containing 
complexes. Int J Appl Pharm 2017;9:38-46. 
 
